An interventional study of LETSGO app in Gynecologic Cancer, sponsored by Sorlandet Hospital HF. Completed at 1 site in Norway. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by Sorlandet Hospital HF · Not applicable, Interventional, and Supportive care
This pilot study is evaluating a new smartphone application named the LETSGO app. The LETSGO app is designed to promote empowerment in patients after treatment for gynecological cancer.
Gynecological cancer treatment is increasingly successful, resulting in a rising number of cancer survivors. Many gynecological cancer survivors may experience late side effects from their cancer treatment. In addition, evidence is accumulating that an active lifestyle may increase empowerment and may positively influence well-being after cancer treatment. Through the LETSGO smartphone app, women treated for gynecological cancer will get access to individualized posttreatment information on side effects as well as tailored physical activity advices in order to assume more responsibility for achieving the best outcomes from her care. The participants will also regularly answer patient reported outcomes regarding possible recurrence though the app. As a first step the smart-phone application will be pilot-tested.
154 studies on the registry are indexed under Empowerment; 31 are open to participants now.
This study's enrollment of 24 is below the median of 141 across 132 interventional studies indexed under Empowerment.
Browse Empowerment studies →Sorlandet Hospital HF is the lead sponsor of 74 studies on the registry; 12 are open to participants now.
Compared within Empowerment, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
Device: LETSGO app
Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
Satisfaction with LETSGOapp
Evaluate satisfaction with app through patient interviews
Time frame: 8 months
Recruitment rate
Evaluate the patient recruitment rate
Time frame: 6 months
Acceptability of goal setting
Evaluate acceptability of goalsetting through changes in Activity level
Time frame: 8 months
Plan to share: No — This is a pilot study
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in May 2019, 14 months.
Of 82 non-industry interventional studies with no phase under Empowerment, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's 14 months is below that.
Counting every sponsor, half of 82 studies reached it within 22 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sorlandet Hospital HF